Cancer - Oncology

Head & Neck Cancer

The Mount Sinai Health System is globally recognized for its minimally invasive treatments and world renowned head and neck specialists. Dr. Eric M. Genden, Chair of the Department of Otolaryngology – Head and Neck Surgery was the first to perform transoral robotic surgery (TORS) for oropharyngeal cancers in New York in 2009. Mount Sinai’s Head and Neck Cancer Program is a multidisciplinary team offering patients robotic and minimally invasive treatments, as well as the most current options for immunotherapy and clinical trials.

This leading team of head and neck cancer physicians treat:

  • Larynx cancer
  • Oral cancer
  • Parathyroid cancer
  • Salivary gland disorders and cancer
  • Sinus cancer
  • Skin cancers of the face
  • Throat cancer
  • Thyroid disorders and cancer
  • Tracheal cancer 

Multidisciplinary Head and Neck Cancer Care Team at Mount Sinai

Head and neck cancers are complex disease processes, which affect various structures of the mouth, jaw and throat. The delicate nature of these systems and goal of preservation of each is why you or your loved one will need a team of specialists. Our care philosophy incorporates this team effort at each phase of your care.

Patients are entered into our Patient First Program, which is a personalized team dedicated to coordinating the care of our patients. This multidisciplinary team collaborates with you and your referring physician to identify the best approach to care. Specialists include head and neck surgeons, microvascular and reconstructive surgeons, oral and maxillofacial surgeons, medical and radiation oncologists, oncology nurse practitioners and nurses, speech and hearing therapists, social workers and nutritionists. 

Innovative Head and Neck Cancer Research

Mount Sinai offers you and your loved one access to institutional and multi-institutional clinical trials. At the Head and Neck Cancer Research Program, our faculty and researchers are studying immunotherapies, the reduction of medical oncology after TORS, the transmission of HPV (human papillomavirus) and its effect on oropharyngeal cancers, the reduction in side effects, the quality of life with TORS versus open surgery and the correlation of environmental toxins and thyroid cancer. This distinguished Research Program is also internationally recognized as a leading resource for tumor cell dormancy research. 

Why Choose Mount Sinai for Head and Neck Cancer Care

At Mount Sinai, our patients have the following distinct care advantages:

  • Foremost minimally invasive head and neck surgeons
  • State-of-the-art technology, including TORS and sialendoscopy
  • Microvascular, reconstructive and oral and maxillofacial surgeons
  • Unmatched experience with HPV-related oropharyngeal cancers
  • Multidisciplinary (team) approach 
  • Medical and Radiation Oncology Surveillance Program during and post-treatment
  • Participation to clinical trials (optional and pending candidacy)
  • Easy access to care, including participation in most insurances

For more information about the diagnosis and treatments of head and neck cancers at the Mount Sinai Health System, please visit Mount Sinai’s Head and Neck Institute.